Form 8-K - Current report:
SEC Accession No. 0001493152-25-003619
Filing Date
2025-01-24
Accepted
2025-01-24 17:00:31
Documents
15
Period of Report
2025-01-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47217
2 ex10-1.htm EX-10.1 15082
  Complete submission text file 0001493152-25-003619.txt   289387

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cing-20250117.xsd EX-101.SCH 3781
4 XBRL DEFINITION FILE cing-20250117_def.xml EX-101.DEF 30042
5 XBRL LABEL FILE cing-20250117_lab.xml EX-101.LAB 36718
6 XBRL PRESENTATION FILE cing-20250117_pre.xml EX-101.PRE 27065
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5723
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 25554876
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)